TFRC and neoplasm: Studies suggest that TFR‐1 could be targeted in order to deliver therapeutic agents into tumour cells by receptor‐mediated endocytosis, or to inhibit cell growth and/or induce apoptosis in malignant cells using cytotoxic anti‐TFR‐1 antibodies (Daniels, Delgado, Helguera, et al., 2006; Daniels, Delgado, Rodriguez, et al., 2006).